Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Abbvie Inc (ABBV)

Abbvie Inc (ABBV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Abbvie Inc 1 NORTH WAUKEGAN ROAD NORTH CHICAGO IL 60064 USA

www.abbvie.com Employees: 55,000 P: 847-932-7900

Sector:

Medical

Description:

AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi and Rinvoq position it well for long-term growth. AbbVie came into existence after Abbott Laboratories divested its pharmaceutical division. AbbVie enjoys leadership positions in key therapeutic areas including immunology, hematologic oncology, neuroscience, aesthetics, eye care and womens' health. Humira is approved for several autoimmune diseases like rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease and others. Imbruvica became part of the company's portfolio following the Pharmacyclics acquisition. Other key drugs include Venclexta, Botox Cosmetic, Botox Therapeutics, Vraylar, Skyrizi and Rinvoq.

Key Statistics

Overview:

Market Capitalization, $K 373,849,248
Enterprise Value, $K 435,469,248
Shares Outstanding, K 1,765,355
Annual Sales, $ 56,334 M
Annual Net Income, $ 4,278 M
Last Quarter Sales, $ 15,102 M
Last Quarter Net Income, $ -22,000 K
EBIT, $ 9,130 M
EBITDA, $ 17,516 M
60-Month Beta 0.61
% of Insider Shareholders 0.25%
% of Institutional Shareholders 70.23%
Float, K 1,760,942
% Float 99.75%
Short Volume Ratio 0.49

Growth:

1-Year Return 16.87%
3-Year Return 33.02%
5-Year Return 207.72%
5-Year Revenue Growth 69.34%
5-Year Earnings Growth 13.20%
5-Year Dividend Growth 44.86%

Per-Share Information:

Most Recent Earnings 2.16 on 01/31/25
Next Earnings Date 04/25/25
Earnings Per Share ttm 10.12
EPS Growth vs. Prev Qtr -28.00%
EPS Growth vs. Prev Year -22.58%
Annual Dividend Rate, $ 6.29
Annual Dividend Yield 2.97%
Most Recent Dividend 1.640 on 01/15/25
Next Ex-Dividends Date 04/15/25
Dividend Payable Date 05/15/25
Dividend Payout Ratio 60.85%

ABBV Ratios

Ratio
Price/Earnings ttm 20.90
Price/Earnings forward 17.19
Price/Earnings to Growth 1.44
Return-on-Equity % 296.28%
Return-on-Assets % 12.65%
Profit Margin % 7.59%
Debt/Equity 19.96
Price/Sales 6.63
Price/Cash Flow 14.17
Price/Book 111.13
Book Value/Share 1.90
Interest Coverage 2.72

ABBV Dividends

Date Value
01/15/25 $1.6400
10/15/24 $1.5500
07/15/24 $1.5500
04/12/24 $1.5500
01/12/24 $1.5500
10/12/23 $1.4800
07/13/23 $1.4800
04/13/23 $1.4800
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar